Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Vet J ; 205(2): 281-7, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25190293

RESUMEN

Osteosarcoma is the most common primary bone tumour in dogs but various forms of therapy have not significantly improved clinical outcomes. As dysregulation of kinase activity is often present in tumours, kinases represent attractive molecular targets for cancer therapy. The purpose of this study was to identify novel compounds targeting kinases with the potential to induce cell death in a panel of canine osteosarcoma cell lines. The ability of 80 well-characterized kinase inhibitor compounds to inhibit the proliferation of four canine osteosarcoma cell lines was investigated in vitro. For those compounds with activity, the mechanism of action and capability to potentiate the activity of doxorubicin was further evaluated. The screening showed 22 different kinase inhibitors that induced significant anti-proliferative effects across the four canine osteosarcoma cell lines investigated. Four of these compounds (RO 31-8220, 5-iodotubercidin, BAY 11-7082 and an erbstatin analog) showed significant cell growth inhibitory effects across all cell lines in association with variable induction of apoptosis. RO 31-8220 and 5-iodotubercidin showed the highest ability to potentiate the effects of doxorubicin on cell viability. In conclusion, the present study identified several potent kinase inhibitors targeting the PKC, CK1, PKA, ErbB2, mTOR and NF-κB pathways, which may warrant further investigations for the treatment of osteosarcoma in dogs.


Asunto(s)
Antineoplásicos/farmacología , Enfermedades de los Perros/tratamiento farmacológico , Osteosarcoma/veterinaria , Inhibidores de Proteínas Quinasas/farmacología , Animales , Línea Celular Tumoral , Supervivencia Celular , Perros , Osteosarcoma/tratamiento farmacológico
2.
Am J Vet Res ; 73(11): 1824-31, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23106471

RESUMEN

OBJECTIVE: To characterize acute inflammatory and hemostatic surgical stress responses following castration in cats and to evaluate whether the addition of local anesthesia to the anesthetic protocol attenuates these responses. ANIMALS: 39 male cats. PROCEDURES: Cats undergoing castration were randomly assigned to 2 groups: both groups underwent surgery with general anesthesia, and 1 group additionally received a local anesthetic (lidocaine [2.0 mg/kg in total, divided intratesticularly and SC]) prior to incision. Blood samples were collected after anesthetic induction (baseline) and 1, 5, and 24 hours later. Thromboelastography and coagulation variables (activated partial thromboplastin time [aPTT] and prothrombin time [PT]) were analyzed; fibrinolysis was assessed with plasma D-dimer concentrations. The acute-phase response was evaluated via measurement of plasma fibrinogen and serum amyloid A (last time point, 28 hours) concentrations. Hematologic variables were analyzed at baseline and 1, 5, and 24 hours later. RESULTS: Evidence of hemostatic and inflammatory activation after surgery was detected in both groups. Maximum amplitude and G (global clot strength) were significantly increased at 24 hours, and significant, but not clinically relevant, decreases were detected in aPTT at 5 and 24 hours and in PT at 24 hours, compared with baseline values. Serum amyloid A concentrations were significantly higher at 24 and 28 hours than at baseline, and plasma fibrinogen concentration was significantly increased at 24 hours; WBC and RBC counts and Hct were significantly increased at multiple time points. No differences between groups were detected for any variables. CONCLUSIONS AND CLINICAL RELEVANCE: Castration appeared to induce hypercoagulability and an acute-phase inflammatory response in cats. Local anesthesia with lidocaine did not attenuate this response.


Asunto(s)
Anestesia General/veterinaria , Anestesia Local/veterinaria , Inflamación/veterinaria , Orquiectomía/veterinaria , Estrés Fisiológico/efectos de los fármacos , Anestesia por Inhalación/veterinaria , Anestésicos Locales/farmacología , Animales , Gatos , Inflamación/prevención & control , Isoflurano/farmacología , Lidocaína , Masculino , Orquiectomía/métodos , Dolor/prevención & control , Dolor/veterinaria
3.
Vet Surg ; 37(5): 472-8, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18986315

RESUMEN

OBJECTIVE: To evaluate efficacy of hypotonic water as adjuvant therapy after marginal resection of canine mast cell tumors (MCT). STUDY DESIGN: Double-blinded, placebo-controlled, prospective, randomized study. ANIMALS: Dogs (n=30) with spontaneous, cutaneous, solitary MCT. METHODS: The wound bed of MCT, resected with margins <0.5 cm, was injected with either hypotonic or isotonic water according to a standardized protocol. Follow-up was obtained by clinical examination at 1, 2, 3, 6, and 12 months and annual telephone contact with the owner. RESULTS: Eighteen dogs were treated with isotonic lactated Ringer's solution and 12 dogs with hypotonic distilled water. All MCT were stage 0 tumors and most grade II. Six tumors (4 isotonic, 2 hypotonic) recurred locally, 3 of these dogs died from disease-related reasons within 4 months. The surviving 3 dogs were alive with a median survival time (ST) of 1092 days. The calculated 2-year recurrence-free rate was 92.7%; the 2-year disease-free rate 79.1%; and the 2-year survival rate 89.5%. No significant differences in local recurrence and ST were observed between treatment groups. Histologic grading was the only significant prognosticator for ST and recurrence-free periods. CONCLUSION: No significant differences in local recurrence and ST were observed between adjunctive hypotonic water and placebo treatment after marginal resection of solitary MCT. CLINICAL RELEVANCE: Hypotonic water does not decrease the rate of local recurrence in dogs with solitary MCT after marginal surgical excision.


Asunto(s)
Enfermedades de los Perros/tratamiento farmacológico , Soluciones Hipotónicas/uso terapéutico , Sarcoma de Mastocitos/veterinaria , Neoplasias Cutáneas/veterinaria , Animales , Quimioterapia Adyuvante/veterinaria , Terapia Combinada , Supervivencia sin Enfermedad , Enfermedades de los Perros/mortalidad , Enfermedades de los Perros/cirugía , Perros , Método Doble Ciego , Femenino , Estudios de Seguimiento , Masculino , Sarcoma de Mastocitos/tratamiento farmacológico , Sarcoma de Mastocitos/mortalidad , Sarcoma de Mastocitos/cirugía , Recurrencia Local de Neoplasia/epidemiología , Recurrencia Local de Neoplasia/veterinaria , Estudios Prospectivos , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/mortalidad , Neoplasias Cutáneas/cirugía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA